Mydriasis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Ocuphire (Nyxol/Phentolamine Ophthalmic Solution), Omeros, Eyenovia

Mydriasis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies -  Ocuphire (Nyxol/Phentolamine Ophthalmic Solution), Omeros, Eyenovia
Delveinsight Business Research LLP
The Mydriasis market size in the 7MM was found to be USD 174 million in 2020, which is anticipated to grow by 2032. The market is expected to grow owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies in the market.

DelveInsight’s “Mydriasis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Mydriasis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Mydriasis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

“On February 13, 2023, Ocuphire Pharma, Inc. (Nasdaq: OCUP) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Nyxol® (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis (RM). The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of September 28, 2023.”


Mydriasis Market

Mydriasis: An Overview

Mydriasis is pupil dilation, which may be due to a non-physiological cause such as disease, trauma, drug usage, or physiological pupillary response. A mydriatic is an agent that induces pupil dilation; it is routinely used to aid the examination of the eye’s retina and other deep structures. In general medical practice, the most frequent indication for pupil dilation is in the screening of diabetic retinopathy, followed by macular degeneration.

This condition can be a symptom of an injury to the brain from physical trauma or a stroke and can affect one pupil at a time or both at once. The pupillary dilation pathway is controlled by the iris dilator muscle, which consists of fibers that are oriented radially, and connect the exterior of the iris with the interior. When the dilator muscle contracts, it pulls the interior of the iris outward, thus increasing the size of the pupil. Furthermore, the iris dilator muscle is controlled by the sympathetic nervous system, the part of the autonomic nervous system that is involved in arousal, wakefulness, and the fight or flight response.

Mydriasis Market Key Facts

  • Among the EU-5 countries, Germany accounted for the highest market size for Mydriasis, followed by France, Italy, UK, and Spain.

  • Among the 7MM, the US accounted for 88% of the overall market size of Mydriasis in 2020.

  • The total diagnosed prevalent population of Mydriasis in the 7MM countries was estimated to be 8.06 million cases in 2020.

  • France had the highest number of cataract surgeries among the European countries, with approximately 0.88 million procedures in 2020.

  • Japan had 0.47 million prevalent cases in 2020, which is expected to increase by 2032.

  • As cataract usually affects the aged more than the young, the age-specific cases show peak distribution between 70 and 79 years. In the United States, 1.43 million procedures were performed within this age group (70–79) in 2020, which is expected to rise by 2030.

  • In 2020, cataract surgery numbers in the US varied according to gender, such as 2.20 million and 1.46 million procedures for females and males, respectively. 

Mydriasis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Mydriasis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Mydriasis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Mydriasis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Mydriasis Epidemiology, Segmented by –

  • Total Prevalent cases of Mydriasis (2019–2032)

  • Gender-specific cases of Mydriasis (2019–2032)

  • Age-specific cases of Mydriasis (2019–2032)

Mydriasis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mydriasis market or expected to be launched during the study period. The analysis covers the Mydriasis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mydriasis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Mydriasis Market Will Evolve and Grow by 2032 @

Mydriasis Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Mydriasis. Currently, Ocuphire Pharma, Inc. is leading the therapeutics market with its Mydriasis drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the Mydriasis Therapeutics Market Include:

  • Théa Laboratories

  • Omeros Corporation

  • Ocuphire Pharma

  • Eyenovia Inc.

Mydriasis Therapies Covered in the Report Include:

  • Phentolamine Ophthalmic Solution – Ocuphire Pharma


The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Mydriasis Competitive Intelligence Analysis

4. Mydriasis Market Overview at a Glance

5. Mydriasis Disease Background and Overview

6. Mydriasis Patient Journey

7. Mydriasis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Mydriasis Treatment Algorithm, Current Treatment, and Medical Practices

9. Mydriasis Unmet Needs

10. Key Endpoints of Mydriasis Treatment

11. Mydriasis Marketed Products

12. Mydriasis Emerging Drugs and Latest Therapeutic Advances

13. Mydriasis Seven Major Market Analysis

14. Attribute Analysis

15. Mydriasis Market Outlook (In US, EU5, and Japan)

16. Mydriasis Access and Reimbursement Overview

17. KOL Views on the Mydriasis Market

18. Mydriasis Market Drivers

19. Mydriasis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsigh
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch to discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States